Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361996/
https://www.ncbi.nlm.nih.gov/pubmed/32661117
http://dx.doi.org/10.1136/jitc-2019-000391corr1
_version_ 1783559428901961728
collection PubMed
description
format Online
Article
Text
id pubmed-7361996
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73619962020-07-16 Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma J Immunother Cancer Correction BMJ Publishing Group 2020-07-12 /pmc/articles/PMC7361996/ /pubmed/32661117 http://dx.doi.org/10.1136/jitc-2019-000391corr1 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Correction
Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
title Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
title_full Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
title_fullStr Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
title_full_unstemmed Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
title_short Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
title_sort correction: overall survival at 5 years of follow-up in a phase iii trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361996/
https://www.ncbi.nlm.nih.gov/pubmed/32661117
http://dx.doi.org/10.1136/jitc-2019-000391corr1

Ejemplares similares